Evidence map›Paper›PMID 34852007›Full record

ArticlePloS one2021

Improved performance and consistency of deep learning 3D liver segmentation with heterogeneous cancer stages in magnetic resonance imaging.

Moritz Gross, Michael Spektor, Ariel Jaffe, Ahmet S Kucukkaya, Simon Iseke, Stefan P Haider, Mario Strazzabosco, Julius Chapiro, John A Onofrey

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. LI-RADS-based hepatocellular carcinoma risk mapping using contrast-enhanced MRI and self-configuring deep learning.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 2 countries.

Moritz GrossDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, United States of America.ORCID 0000-0002-6831-5004
Michael SpektorDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Ariel JaffeDepartment of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Ahmet S KucukkayaDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Simon IsekeDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Stefan P HaiderDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, United States of America.ORCID 0000-0002-7640-3645
Mario StrazzaboscoDepartment of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Julius ChapiroDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, United States of America.
John A OnofreyDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, Connecticut, United States of America.
Yale University · US

Funding

Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
NIDDK NIH HHS P30 DK034989
6 · The paper itself

Abstract

purposeAccurate liver segmentation is key for volumetry assessment to guide treatment decisions. Moreover, it is an important pre-processing step for cancer detection algorithms. Liver segmentation can be especially challenging in patients with cancer-related tissue changes and shape deformation. The aim of this study was to assess the ability of state-of-the-art deep learning 3D liver segmentation algorithms to generalize across all different Barcelona Clinic Liver Cancer (BCLC) liver cancer stages.

methodsThis retrospective study, included patients from an institutional database that had arterial-phase T1-weighted magnetic resonance images with corresponding manual liver segmentations. The data was split into 70/15/15% for training/validation/testing each proportionally equal across BCLC stages. Two 3D convolutional neural networks were trained using identical U-net-derived architectures with equal sized training datasets: one spanning all BCLC stages ("All-Stage-Net": AS-Net), and one limited to early and intermediate BCLC stages ("Early-Intermediate-Stage-Net": EIS-Net). Segmentation accuracy was evaluated by the Dice Similarity Coefficient (DSC) on a dataset spanning all BCLC stages and a Wilcoxon signed-rank test was used for pairwise comparisons.

results219 subjects met the inclusion criteria (170 males, 49 females, 62.8±9.1 years) from all BCLC stages. Both networks were trained using 129 subjects: AS-Net training comprised 19, 74, 18, 8, and 10 BCLC 0, A, B, C, and D patients, respectively; EIS-Net training comprised 21, 86, and 22 BCLC 0, A, and B patients, respectively. DSCs (mean±SD) were 0.954±0.018 and 0.946±0.032 for AS-Net and EIS-Net (p<0.001), respectively. The AS-Net 0.956±0.014 significantly outperformed the EIS-Net 0.941±0.038 on advanced BCLC stages (p<0.001) and yielded similarly good segmentation performance on early and intermediate stages (AS-Net: 0.952±0.021; EIS-Net: 0.949±0.027; p = 0.107).

conclusionTo ensure robust segmentation performance across cancer stages that is independent of liver shape deformation and tumor burden, it is critical to train deep learning models on heterogeneous imaging data spanning all BCLC stages.

Indexed as

Deep LearningFemaleHumansImage Processing, Computer-AssistedLiverLiver NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedNeural Networks, ComputerRetrospective StudiesTumor Burden

Identifiers

PMID34852007
PMCPMC8635384
OpenAlexW3214856959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.